CLNN Clene Inc.

Clene is revolutionizing the treatment of neurodegenerative disease with an innovative nanotherapeutic platform to generate first-in-class elemental nanomedicines designed to optimize neurorepair and health through energy-enhancing bioenergetic catalysis.

$2.52  -0.13 (-4.91%)
As of 06/30/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/27/2018
Outstanding shares:  63,256,545
Average volume:  524,692
Market cap:   $167,629,844
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMW2FV3
Valuation   (See tab for details)
PE ratio:   9.57
PB ratio:   78.75
PS ratio:   842.36
Return on equity:   1,488.15%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy